Single administration of intracameral bimatoprost implant: IOP lowering, safety

Conferences|AAO

Michael R. Robinson, MD, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, shares the highlights of the study "Single administration of intracameral bimatoprost implant 10 µg: IOP lowering and safety," presented during the virtual AAO 2020 meeting.

See more AAO coverage here

Related Videos
Related Content

Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023

Glaucoma 360: Drug targets and reduces episcleral venous pressure in glaucoma

February 3rd 2023

Uveitis, flare ups and challenges in clinical trials

April 12th 2022

International Keratoconus Academy continues to provide cutting-edge education

February 2nd 2023

Highlighting results from first FDA-reported study for treatment of presbyopia

September 27th 2021

Pharmacotherapies taking center stage at Angiogenesis, Exudation, and Degeneration 2023

February 1st 2023

Eyenuk gets greenlight to market AI screening system in European Union

January 31st 2023
Advertise
Privacy
Editorial
Terms and Conditions
Contact Us
Do Not Sell My Personal Information
Job Board
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.